VERAXA Biotech (NASDAQ: VRXA), a developer of next-generation antibody-based cancer therapies, provided an update on its strategy to implement U.S. Food and Drug Administration-aligned New Approach Methodologies (NAMs) across its preclinical research and development programs. The company said the approach could accelerate clinical advancement, reduce development costs and timelines, and significantly reduce animal testing.
VERAXA has built a panel of NAMs to characterize and de-risk its pipeline of BiTAC-based T cell engagers, antibody-drug conjugates (ADCs), and bispecific antibody-drug conjugates (bsADCs). The company said its lead BiTAC-TCE and bsADC candidates were also evaluated using an ex vivo panel of 10 low-passage patient-derived xenograft models of non-small cell lung cancer. The panel required about 10 mice in total, compared with an estimated 200 or more for comparable in vivo efficacy studies. Across the panel, the combined BiTAC consistently induced potent T cell-mediated killing, supporting the company’s dual-targeting approach and demonstrating how its NAM strategy can reduce animal use and preclinical cycle time without compromising clinical relevance.
The implications of this announcement are significant for both investors and the broader biopharmaceutical industry. By aligning with FDA’s push for NAMs, VERAXA positions itself at the forefront of a regulatory shift that favors human-relevant testing methods over traditional animal models. This could lead to faster clinical trials, lower costs, and a reduced ethical burden. For patients, it may mean quicker access to innovative cancer therapies. For the industry, it sets a precedent that could encourage wider adoption of NAMs, potentially transforming preclinical development standards.
VERAXA’s lead candidates are based on its proprietary BiTAC format, a bispecific T cell engager designed to target two antigens simultaneously. The company was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research. BiTAC is a registered trademark of VERAXA Biotech GmbH. The full press release is available at https://ibn.fm/9YRJw, and the original release can be viewed on www.newmediawire.com.
For more information about VERAXA Biotech, visit VERAXA Biotech (NASDAQ: VRXA). The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA. Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.ai/Disclaimer.
This news matters because it highlights a tangible step toward reducing animal testing in drug development while maintaining scientific rigor. As regulatory agencies increasingly accept NAMs, companies like VERAXA that invest in these methods may gain a competitive edge. The reduction from 200 mice to 10 for a key efficacy study is a compelling proof point that could influence how other biotechs design their preclinical programs. Moreover, the successful application of NAMs to complex biologics like BiTACs and bsADCs demonstrates that these methods are not limited to simple compounds, broadening their potential impact across oncology and beyond.
